Comparison of Lung-Homing Receptor Expression and Activation Profiles on NK Cell and T Cell Subsets in COVID-19 and Influenza.
COVID-19
NK cells
SARS-CoV-2
T cells
chemokine receptors
influenza
lung-homing
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
12
2021
accepted:
24
02
2022
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Respiratory viral infections with SARS-CoV-2 and influenza viruses commonly induce a strong infiltration of immune cells into the human lung, with potential detrimental effects on the integrity of the lung tissue. Despite comprising the largest fractions of circulating lymphocytes in the lung, rather little is known about how peripheral blood natural killer (NK) cell and T cell subsets are equipped for lung-homing in COVID-19 and influenza. Here, we provide a detailed comparative analysis of NK cells and T cells in patients infected with SARS-CoV-2 or influenza virus, focusing on the protein and gene expression of chemokine receptors known to be involved in recruitment to the lung. For this, we used 28-colour flow cytometry as well as re-analysis of a publicly available single-cell RNA-seq dataset from bronchoalveolar lavage (BAL) fluid. Frequencies of NK cells and T cells expressing CXCR3, CXCR6, and CCR5 were altered in peripheral blood of COVID-19 and influenza patients, in line with increased transcript expression of
Identifiants
pubmed: 35371005
doi: 10.3389/fimmu.2022.834862
pmc: PMC8966396
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
834862Informations de copyright
Copyright © 2022 Brownlie, Rødahl, Varnaite, Asgeirsson, Glans, Falck-Jones, Vangeti, Buggert, Ljunggren, Michaëlsson, Gredmark-Russ, Smed-Sörensen and Marquardt.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Immunol. 2019 May 17;10:1116
pubmed: 31156653
Sci Adv. 2020 Dec 9;6(50):
pubmed: 33187979
PLoS One. 2014 Feb 05;9(2):e86912
pubmed: 24505273
J Immunol. 2021 Sep 1;207(5):1229-1238
pubmed: 34348975
J Infect Dis. 2006 Jul 1;194(1):61-70
pubmed: 16741883
Comput Struct Biotechnol J. 2021;19:976-988
pubmed: 33558827
Sci Rep. 2021 Jun 1;11(1):11524
pubmed: 34075155
Signal Transduct Target Ther. 2021 Sep 1;6(1):328
pubmed: 34471088
Mol Med. 2021 Oct 18;27(1):129
pubmed: 34663207
Cytokine. 2022 Apr;152:155810
pubmed: 35121493
Nature. 2001 Feb 22;409(6823):1055-60
pubmed: 11234016
J Clin Invest. 2021 Mar 15;131(6):
pubmed: 33492309
Front Immunol. 2021 Dec 06;12:763292
pubmed: 34938289
Cell Immunol. 2022 Jan;371:104454
pubmed: 34773897
Am J Respir Crit Care Med. 2005 Apr 15;171(8):850-7
pubmed: 15657466
Nat Rev Immunol. 2022 Feb;22(2):112-123
pubmed: 34117484
Curr Pathobiol Rep. 2021;9(4):93-105
pubmed: 34900402
Cell Rep. 2021 Jul 20;36(3):109414
pubmed: 34260965
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
Sci Immunol. 2020 Jul 10;5(49):
pubmed: 32651212
Am J Pathol. 2000 Jun;156(6):1951-9
pubmed: 10854218
Sci Immunol. 2020 Aug 21;5(50):
pubmed: 32826343
Eur J Immunol. 2008 Dec;38(12):3376-87
pubmed: 19039768
Immunity. 2021 Apr 13;54(4):797-814.e6
pubmed: 33765436
Nat Rev Nephrol. 2021 Jan;17(1):46-64
pubmed: 33077917
Microb Pathog. 2021 Mar;152:104554
pubmed: 33157216
Lancet. 2004 Feb 21;363(9409):617-9
pubmed: 14987888
Signal Transduct Target Ther. 2020 Jun 19;5(1):100
pubmed: 32561706
Crit Care. 2020 Nov 2;24(1):632
pubmed: 33138839
Front Immunol. 2018 Apr 17;9:781
pubmed: 29719539
Nat Commun. 2019 Aug 26;10(1):3841
pubmed: 31451696
Nat Med. 2006 Oct;12(10):1203-7
pubmed: 16964257
Allergy. 2020 Nov;75(11):2829-2845
pubmed: 32496587
Am J Respir Crit Care Med. 2013 Jan 1;187(1):65-77
pubmed: 23144331
J Leukoc Biol. 2004 Oct;76(4):886-95
pubmed: 15240757
Am J Pathol. 2013 Oct;183(4):1258-1268
pubmed: 23938324
J Virol. 2009 Sep;83(18):9215-22
pubmed: 19587043
Chin Med J (Engl). 2020 May 5;133(9):1087-1095
pubmed: 32358325
Nat Rev Immunol. 2020 Jul;20(7):389-391
pubmed: 32439870
PLoS Biol. 2020 Sep 8;18(9):e3000849
pubmed: 32898168
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
Nat Biotechnol. 2020 Aug;38(8):970-979
pubmed: 32591762
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Immunity. 2008 Jul 18;29(1):101-13
pubmed: 18617426
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409
pubmed: 32270184
J Exp Med. 2012 Mar 12;209(3):551-63
pubmed: 22370717
J Immunol. 2019 Dec 15;203(12):3179-3189
pubmed: 31740485
Nat Rev Immunol. 2021 Jan;21(1):49-64
pubmed: 33214719
J Exp Med. 2019 Dec 2;216(12):2748-2762
pubmed: 31558615
Cell Res. 2013 Apr;23(4):577-80
pubmed: 23419516